Plain-English translation of NCT06555068 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new drug called HRS-6209 combined with several other existing or experimental medications to see if they can help people with advanced breast cancer. Researchers want to understand how safe the medication is, how your body processes it, and whether these combinations actually help shrink or slow down cancer growth.
Advanced breast cancer that has spread or cannot be surgically removed is very difficult to treat, and current options don't work for everyone. This trial is exploring whether combining this new treatment with other approved or promising drugs might give patients more effective choices.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take the new medication HRS-6209 by mouth in combination with one of several other drugs, depending on which treatment group you are assigned to. You will have regular clinic visits for blood tests, imaging scans, heart monitoring, and other check-ups to measure how well the treatment is working and watch for any side effects. The study has different phases to first check safety and dosing, then expand to test effectiveness in more patients.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
China